Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Accuray Incorporated ARAY

Healthcare  —  Medical Devices
0.22 0.00 0.00% as of 25 Sep
Market cap
$27.8M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Accuray Incorporated (ARAY) Business Profile

Updated before January 2025

Company Overview

Accuray Incorporated (NASDAQ: ARAY) is a global leader in the development, manufacturing, and sale of innovative radiation therapy systems for the treatment of cancer and other diseases. Founded in 1990 and headquartered in Sunnyvale, California, Accuray has been at the forefront of advancing precision radiation therapy technologies. The company was established by John R. Adler, a neurosurgeon and professor at Stanford University, who envisioned a more accurate and effective way to deliver radiation therapy to patients. Over the years, Accuray has grown into a trusted name in the healthcare industry, with a strong commitment to improving patient outcomes and enhancing the quality of life for individuals undergoing cancer treatment.

Accuray’s leadership team is composed of experienced professionals with deep expertise in healthcare, technology, and business management. The company’s CEO, Suzanne Winter, brings a wealth of experience in the medical device industry, driving innovation and strategic growth. Under her leadership, Accuray continues to expand its global footprint and strengthen its position as a pioneer in radiation oncology.

Core Business Segments

Accuray operates in the medical technology sector, focusing on radiation therapy systems. The company’s core business segments include:

1. CyberKnife® Systems

The CyberKnife® System is a robotic radiosurgery system designed to deliver high-precision radiation therapy to tumors anywhere in the body. It is particularly effective for treating complex cases, such as brain, spine, and lung tumors. The system uses real-time imaging and robotic technology to track tumor movement and deliver radiation with sub-millimeter accuracy, minimizing damage to surrounding healthy tissues.

2. TomoTherapy® Systems

The TomoTherapy® System is an advanced radiation therapy platform that integrates CT imaging with intensity-modulated radiation therapy (IMRT). This system is ideal for treating a wide range of cancers, including head and neck, breast, and prostate cancers. Its unique helical delivery method ensures precise and uniform radiation dose distribution, improving treatment outcomes.

3. Radixact® Systems

The Radixact® System is the next-generation TomoTherapy platform, offering enhanced treatment planning, delivery, and adaptive therapy capabilities. It is designed to provide personalized treatment plans for patients, ensuring optimal results. The system’s integrated imaging and adaptive therapy features make it a versatile solution for various cancer types.

4. Service and Support

Accuray also offers comprehensive service and support programs to ensure the optimal performance of its radiation therapy systems. These services include maintenance, training, and software upgrades, enabling healthcare providers to deliver the highest standard of care to their patients.

Business Model

Accuray’s business model revolves around the integration of cutting-edge technology, comprehensive services, and a customer-centric approach. The company generates revenue through the sale of its radiation therapy systems, as well as recurring revenue streams from service contracts, software upgrades, and consumables. By offering a combination of innovative products and reliable support services, Accuray ensures long-term partnerships with healthcare providers and institutions.

The company’s focus on research and development (R&D) is a key driver of its business model. Accuray invests heavily in R&D to develop new technologies and improve existing products, maintaining its competitive edge in the market. Additionally, the company collaborates with leading academic and research institutions to advance the field of radiation oncology.

Strategic Direction

Accuray is committed to driving innovation and expanding access to advanced radiation therapy solutions worldwide. The company’s strategic priorities include:

  • Expanding Global Reach: Accuray aims to increase its presence in emerging markets, where the demand for advanced cancer treatment solutions is growing rapidly. The company is focused on building partnerships with local distributors and healthcare providers to penetrate these markets effectively.
  • Enhancing Product Portfolio: Accuray continues to invest in R&D to develop new products and improve existing systems. The company is exploring opportunities to integrate artificial intelligence (AI) and machine learning (ML) technologies into its platforms, enabling more precise and personalized treatment plans.
  • Sustainability Goals: Accuray is committed to reducing its environmental footprint by adopting sustainable practices in its operations and product development processes. The company is also focused on promoting social responsibility and ethical business practices.
  • Improving Patient Outcomes: Accuray’s ultimate goal is to improve patient outcomes by delivering innovative and effective radiation therapy solutions. The company is dedicated to advancing the field of radiation oncology through continuous innovation and collaboration.

Competitive Landscape

Accuray operates in a highly competitive market, facing competition from both established players and emerging companies in the medical technology sector. Key competitors include:

  • Varian Medical Systems (a Siemens Healthineers company): A leading provider of radiation therapy and oncology solutions, Varian offers a wide range of products, including linear accelerators and treatment planning software.
  • Elekta AB: A Swedish company specializing in radiation therapy and radiosurgery systems, Elekta is known for its advanced linear accelerators and brachytherapy solutions.
  • IBA (Ion Beam Applications): A Belgian company focused on proton therapy systems, IBA is a major player in the field of advanced radiation therapy.
  • ViewRay, Inc.: A provider of MRI-guided radiation therapy systems, ViewRay offers innovative solutions for real-time imaging and adaptive therapy.

Accuray differentiates itself through its unique product offerings, such as the CyberKnife and TomoTherapy systems, which provide unparalleled precision and versatility.

Risk Factors

Accuray faces several risks that could impact its business operations and financial performance, including:

  • Market Dependence: The company’s revenue is heavily dependent on the sale of its radiation therapy systems and related services. Any decline in demand for these products could adversely affect its financial performance.
  • Supply Chain Disruptions: Accuray relies on a global supply chain for the production of its systems. Disruptions in the supply chain, such as shortages of critical components or delays in manufacturing, could impact the company’s ability to meet customer demand.
  • Regulatory Challenges: The medical technology industry is subject to stringent regulatory requirements. Delays in obtaining regulatory approvals for new products or changes in regulations could affect Accuray’s ability to bring new products to market.
  • Competition: Intense competition from established players and new entrants in the market could impact Accuray’s market share and pricing power.

Recent Developments

Accuray has made significant strides in recent years, introducing new products and expanding its global footprint. Some of the company’s recent developments include:

  • Launch of ClearRT™ Imaging Technology: Accuray introduced ClearRT™, a cutting-edge imaging technology that enhances the precision and accuracy of radiation therapy. This innovation is designed to improve treatment outcomes and patient safety.
  • Partnerships and Collaborations: Accuray has entered into strategic partnerships with leading healthcare providers and research institutions to advance the field of radiation oncology. These collaborations aim to develop new technologies and improve access to advanced cancer treatment solutions.
  • Global Expansion: The company has expanded its presence in key markets, including Asia-Pacific and Europe, through partnerships with local distributors and healthcare providers.

Investment Considerations

Investors considering Accuray as a potential investment should weigh the following strengths and risks:

Strengths:

  • Strong brand recognition and reputation in the radiation oncology market.
  • Innovative product portfolio with unique features and capabilities.
  • Recurring revenue streams from service contracts and software upgrades.
  • Commitment to R&D and continuous innovation.

Risks:

  • Dependence on a limited number of products for revenue generation.
  • Exposure to regulatory and compliance risks.
  • Intense competition from established players and new entrants.
  • Vulnerability to supply chain disruptions and economic uncertainties.

Conclusion

Accuray Incorporated is a leading player in the radiation oncology market, known for its innovative and precise radiation therapy systems. The company’s commitment to improving patient outcomes and advancing the field of radiation oncology positions it as a trusted partner for healthcare providers worldwide. With a strong focus on innovation, global expansion, and sustainability, Accuray is well-positioned for future growth. However, investors should carefully consider the risks associated with the company’s business model and competitive landscape before making investment decisions.